STAT

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

Novartis' contract with Michael Cohen, President Trump's lawyer, isn't its first questionable deal.
Source: Photo illustration: Dom Smith/STAT; Photo: Mark Wilson/Getty Images

When Donald Trump’s lawyer, Michael Cohen, approached Novartis early last year to provide access to the new Trump administration, the company’s response was tone-deaf. But it was hardly a surprise.

The personal lawyer and “fixer” for the president came knocking as big drug makers were anxious about the future, since candidate Trump had for through-the-roof prices. So former Novartis chief executive Joe Jimenez quickly authorized a one-year, . This was considerably more than Novartis Washington lobbyists. And it wasn’t for Cohen’s policy expertise — he knew nothing about health care.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks